BRPI0413035A - sal, composição farmacêutica, uso de um sal, e, método para tratamento, prevenção ou alìvio de uma doença ou distúrbio ou de uma condição - Google Patents

sal, composição farmacêutica, uso de um sal, e, método para tratamento, prevenção ou alìvio de uma doença ou distúrbio ou de uma condição

Info

Publication number
BRPI0413035A
BRPI0413035A BRPI0413035-9A BRPI0413035A BRPI0413035A BR PI0413035 A BRPI0413035 A BR PI0413035A BR PI0413035 A BRPI0413035 A BR PI0413035A BR PI0413035 A BRPI0413035 A BR PI0413035A
Authority
BR
Brazil
Prior art keywords
salt
disorder
disease
condition
pharmaceutical composition
Prior art date
Application number
BRPI0413035-9A
Other languages
English (en)
Inventor
Brian Frostrup
Frank Wotjen
Klaus Snej Jensen
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of BRPI0413035A publication Critical patent/BRPI0413035A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"SAL, COMPOSIçãO FARMACêUTICA, USO DE UM SAL, E, MéTODO PARA TRATAMENTO, PREVENçãO OU ALìVIO DE UMA DOENçA OU DISTúRBIO OU DE UMA CONDIçãO". Esta invenção refere-se a novos sais tartarato de 2-metoximetil-3-(3,4-diclorofenil)-8-azabiciclo¢3,2,1!octano, como monoidratos e anidratos de L-tartarato. Os sais são úteis como inibidores de reabsorção de neurotransmissores monoamina. Em outros aspectos a invenção refere-se ao uso desses sais em um método para terapia e a composições farmacêuticas contendo os sais da invenção.
BRPI0413035-9A 2003-07-31 2004-07-29 sal, composição farmacêutica, uso de um sal, e, método para tratamento, prevenção ou alìvio de uma doença ou distúrbio ou de uma condição BRPI0413035A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301117 2003-07-31
US49409003P 2003-08-12 2003-08-12
PCT/EP2004/051651 WO2005011694A1 (en) 2003-07-31 2004-07-29 2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts

Publications (1)

Publication Number Publication Date
BRPI0413035A true BRPI0413035A (pt) 2006-10-03

Family

ID=36701727

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413035-9A BRPI0413035A (pt) 2003-07-31 2004-07-29 sal, composição farmacêutica, uso de um sal, e, método para tratamento, prevenção ou alìvio de uma doença ou distúrbio ou de uma condição

Country Status (22)

Country Link
US (1) US7700619B2 (pt)
EP (1) EP1651223B1 (pt)
JP (1) JP4711961B2 (pt)
CN (1) CN100427484C (pt)
AR (1) AR045141A1 (pt)
AT (1) ATE355060T1 (pt)
AU (1) AU2004260837C1 (pt)
BR (1) BRPI0413035A (pt)
CA (1) CA2534295A1 (pt)
DE (1) DE602004005048T2 (pt)
DK (1) DK1651223T3 (pt)
ES (1) ES2281827T3 (pt)
MY (1) MY140105A (pt)
NZ (1) NZ544957A (pt)
PL (1) PL1651223T3 (pt)
PT (1) PT1651223E (pt)
RU (1) RU2348631C2 (pt)
SI (1) SI1651223T1 (pt)
TW (1) TW200507844A (pt)
UA (1) UA86025C2 (pt)
WO (1) WO2005011694A1 (pt)
ZA (1) ZA200600756B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006738A2 (en) * 2005-07-12 2007-01-18 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 2 , 3-disubstituted tropanes for the treatment of disorders of sexual desire
WO2007028769A1 (en) * 2005-09-05 2007-03-15 Neurosearch A/S Monoamine neurotransmitter re-uptake inhibitor for neuroprotection
EP1779851A1 (en) * 2005-10-31 2007-05-02 Boehringer Ingelheim Pharma GmbH & Co.KG Treatment of diabetes
GB0703998D0 (en) 2007-03-01 2007-04-11 Glaxo Group Ltd Novel salt
CN116144016B (zh) * 2021-11-23 2025-02-14 上海新阳半导体材料股份有限公司 一种193nm干法光刻胶用添加剂及其制备方法和应用
CN116144014B (zh) * 2021-11-23 2025-02-14 上海新阳半导体材料股份有限公司 一种193nm干法光刻胶用添加剂及其制备方法和应用
CN116144015B (zh) * 2021-11-23 2024-11-19 上海新阳半导体材料股份有限公司 一种193nm干法光刻胶用添加剂及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
GB8923209D0 (en) * 1989-10-14 1989-11-29 Wyeth John & Brother Ltd Heterocyclic compounds
BR9707636A (pt) * 1996-02-22 1999-07-27 Neurosearch As Composto composição farmacêutica uso de um composto e processos para preparar composto e para tratar um distúrbio ou doença de um organismo animal vivo
US7381733B2 (en) * 2001-11-30 2008-06-03 Neurosearch A/S Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases

Also Published As

Publication number Publication date
ATE355060T1 (de) 2006-03-15
AR045141A1 (es) 2005-10-19
DK1651223T3 (da) 2007-06-11
RU2005141065A (ru) 2006-08-10
ZA200600756B (en) 2007-05-30
MY140105A (en) 2009-11-30
PL1651223T3 (pl) 2007-07-31
PT1651223E (pt) 2007-03-30
CN100427484C (zh) 2008-10-22
UA86025C2 (en) 2009-03-25
ES2281827T3 (es) 2007-10-01
AU2004260837A1 (en) 2005-02-10
US7700619B2 (en) 2010-04-20
EP1651223A1 (en) 2006-05-03
RU2348631C2 (ru) 2009-03-10
SI1651223T1 (sl) 2007-08-31
NZ544957A (en) 2009-02-28
WO2005011694A1 (en) 2005-02-10
AU2004260837C1 (en) 2010-08-19
JP4711961B2 (ja) 2011-06-29
JP2007509030A (ja) 2007-04-12
DE602004005048D1 (de) 2007-04-12
TW200507844A (en) 2005-03-01
DE602004005048T2 (de) 2007-08-16
US20070043075A1 (en) 2007-02-22
CA2534295A1 (en) 2005-02-10
CN1822837A (zh) 2006-08-23
EP1651223B1 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BRPI0409211A (pt) composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto
BRPI0511139B8 (pt) compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BRPI0508820B8 (pt) compostos moduladores de receptor de opióide e composição que os compreende
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
EP1933833B8 (en) Therapy for the treatment of overactive bladder
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BRPI0411608A (pt) derivado de 8-aza-biciclo [3.2.1] octano, composição farmacêutica, uso do composto, e, método de tratamento, prevenção ou alìvio de uma doença, um distúrbio ou uma condição de um organismo animal vivo
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0413745A (pt) horário mde dosagem para agentes anticancerìgenos erbb2
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BR0315346A (pt) Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente, formulação farmacêutica e utilização de inibidor de re-apreensão de norepinefrina em combinação com antagonista de 5-h2a
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
WO2008103690A3 (en) Prevention and treatment for osteonecrosis and osteoradionecrosis of the jaw using pdgf and a bone matrix
BRPI0515261A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]